Cargando…

Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation

The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and implicated with fetomaternal tolerance by downregulating the maternal adaptive and innate immune response against the fetus. HLA-G expression correlates with favorable graft outcome in humans and recently promising imm...

Descripción completa

Detalles Bibliográficos
Autores principales: von Websky, Martin W., Kitamura, Koji, Ludwig-Portugall, Isis, Kurts, Christian, von Laffert, Maximilian, LeMaoult, Joel, Carosella, Edgardo D., Abu-Elmagd, Kareem, Kalff, Joerg C., Schäfer, Nico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942037/
https://www.ncbi.nlm.nih.gov/pubmed/27404095
http://dx.doi.org/10.1371/journal.pone.0158907
_version_ 1782442370513502208
author von Websky, Martin W.
Kitamura, Koji
Ludwig-Portugall, Isis
Kurts, Christian
von Laffert, Maximilian
LeMaoult, Joel
Carosella, Edgardo D.
Abu-Elmagd, Kareem
Kalff, Joerg C.
Schäfer, Nico
author_facet von Websky, Martin W.
Kitamura, Koji
Ludwig-Portugall, Isis
Kurts, Christian
von Laffert, Maximilian
LeMaoult, Joel
Carosella, Edgardo D.
Abu-Elmagd, Kareem
Kalff, Joerg C.
Schäfer, Nico
author_sort von Websky, Martin W.
collection PubMed
description The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and implicated with fetomaternal tolerance by downregulating the maternal adaptive and innate immune response against the fetus. HLA-G expression correlates with favorable graft outcome in humans and recently promising immunosuppressive effects of therapeutic HLA-G in experimental transplantation (skin allograft acceptance) were shown. Consequently, we examined this novel therapeutic approach in solid organ transplantation. In this study, therapeutic recombinant HLA-G5 was evaluated for the first time in a solid organ model of acute rejection (ACR) after orthotopic intestinal transplantation (ITX). Allogenic ITX was performed in rats (Brown Norway to Lewis) with and without HLA-G treatment. It was found that HLA-G treatment significantly reduced histologically proven ACR at both an early and late postoperative timepoint (POD 4/7), concomitant to a functionally preserved graft contractility at POD 7. Interestingly, graft infiltration by myeloperoxidase+ cells was significantly reduced at POD7 by HLA-G treatment. Moreover, HLA-G treatment showed an effect on the allogenic T-cell immune response as assessed by flow cytometry: The influx of recipient-derived CD8(+) T-cells into the graft mesenteric lymphnodes at POD7 was significantly reduced while CD4(+) populations were not affected. As a potential mechanism of action, an induction of T-reg populations in the mesenteric lymphnodes was postulated, but flow cytometric analysis of classical CD4(+)/CD25(+)/FoxP3(+)T(reg)-cells showed no significant alteration by HLA-G treatment. The novel therapeutic approach using recombinant HLA-G5 reported herein demonstrates a significant immunosuppressive effect in this model of allogenic experimental intestinal transplantation. This effect may be mediated via inhibition of recipient-derived CD8(+) T-cell populations either directly or by induction of non-classical T(reg) populations.
format Online
Article
Text
id pubmed-4942037
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49420372016-08-01 Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation von Websky, Martin W. Kitamura, Koji Ludwig-Portugall, Isis Kurts, Christian von Laffert, Maximilian LeMaoult, Joel Carosella, Edgardo D. Abu-Elmagd, Kareem Kalff, Joerg C. Schäfer, Nico PLoS One Research Article The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and implicated with fetomaternal tolerance by downregulating the maternal adaptive and innate immune response against the fetus. HLA-G expression correlates with favorable graft outcome in humans and recently promising immunosuppressive effects of therapeutic HLA-G in experimental transplantation (skin allograft acceptance) were shown. Consequently, we examined this novel therapeutic approach in solid organ transplantation. In this study, therapeutic recombinant HLA-G5 was evaluated for the first time in a solid organ model of acute rejection (ACR) after orthotopic intestinal transplantation (ITX). Allogenic ITX was performed in rats (Brown Norway to Lewis) with and without HLA-G treatment. It was found that HLA-G treatment significantly reduced histologically proven ACR at both an early and late postoperative timepoint (POD 4/7), concomitant to a functionally preserved graft contractility at POD 7. Interestingly, graft infiltration by myeloperoxidase+ cells was significantly reduced at POD7 by HLA-G treatment. Moreover, HLA-G treatment showed an effect on the allogenic T-cell immune response as assessed by flow cytometry: The influx of recipient-derived CD8(+) T-cells into the graft mesenteric lymphnodes at POD7 was significantly reduced while CD4(+) populations were not affected. As a potential mechanism of action, an induction of T-reg populations in the mesenteric lymphnodes was postulated, but flow cytometric analysis of classical CD4(+)/CD25(+)/FoxP3(+)T(reg)-cells showed no significant alteration by HLA-G treatment. The novel therapeutic approach using recombinant HLA-G5 reported herein demonstrates a significant immunosuppressive effect in this model of allogenic experimental intestinal transplantation. This effect may be mediated via inhibition of recipient-derived CD8(+) T-cell populations either directly or by induction of non-classical T(reg) populations. Public Library of Science 2016-07-12 /pmc/articles/PMC4942037/ /pubmed/27404095 http://dx.doi.org/10.1371/journal.pone.0158907 Text en © 2016 von Websky et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
von Websky, Martin W.
Kitamura, Koji
Ludwig-Portugall, Isis
Kurts, Christian
von Laffert, Maximilian
LeMaoult, Joel
Carosella, Edgardo D.
Abu-Elmagd, Kareem
Kalff, Joerg C.
Schäfer, Nico
Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation
title Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation
title_full Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation
title_fullStr Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation
title_full_unstemmed Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation
title_short Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation
title_sort recombinant hla-g as tolerogenic immunomodulant in experimental small bowel transplantation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942037/
https://www.ncbi.nlm.nih.gov/pubmed/27404095
http://dx.doi.org/10.1371/journal.pone.0158907
work_keys_str_mv AT vonwebskymartinw recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT kitamurakoji recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT ludwigportugallisis recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT kurtschristian recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT vonlaffertmaximilian recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT lemaoultjoel recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT carosellaedgardod recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT abuelmagdkareem recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT kalffjoergc recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation
AT schafernico recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation